Appendix 3B

New Issue Announcement, Application for Quotation of Additional Securities and Agreement.

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

ACN:		
107 9	903 159	
We (t	he entity) give ASX the following informatio	n.
	t 1 - All issues ust complete the relevant sections (attach sheets if the	ere is not enough space).
1	⁺ Class of ⁺ securities issued or to be issued	Ordinary Shares (RNO)
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	10,937,500
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Fully Paid Ordinary Shares (RNO)

Name of entity:

Rhinomed Limited (ASX: RNO)

⁺ See chapter 19 for defined terms. Appendix 3B Page 1

4	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?	Yes (RNO).
	 If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	
5	Issue price or consideration	Chausa ĆO 022 nan Chaus
3	issue price of consideration	Shares: \$0.032 per Share.
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Private placement of 10,937,500 shares issued at \$0.032 per share to raise \$350,000 before costs.
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h <i>in relation</i> to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	29 October 2014
6c	Number of *securities issued without security holder approval under rule 7.1	10,937,500
6d	Number of teconnities issued with	Nil
ou	Number of *securities issued with security holder approval under rule 7.1A	Nil

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil
6f	Number of securities issued under an exception in rule 7.2	Nil
_		Г.,.
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	Nil
C.I.	15	
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Refer to the attached Annexure 1
7	Dates of entering *securities into uncertificated holdings or despatch of certificates	25 September 2015

Number and *class of all *securities quoted on ASX (*including* the securities in section 2 if applicable)

Number	†Class
614,438,635	Fully Paid Ordinary Shares (RNO)
203,150,000	Listed Options (RNOOA) exercisable at \$0.06 per option on or before 30 April 2017

9 Number and *class of all *securities not quoted on ASX (*including* the securities in section 2 if applicable)

+Class (Options over Ordinary Shares)		
Exercise	Expiration	ASX Code
Price	Date	
\$0.065	30 April 2017	
	Exercise Price	Exercise Expiration Price Date

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Unchanged

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?
12	to the term of the
12	Is the issue renounceable or non-renounceable?
13	Ratio in which the *securities will be offered
14	⁺ Class of ⁺ securities to which the offer relates
15	[†] Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

01/08/2012

17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
	Gross reference rate ran	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
		Γ
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of *security holders	
25	If the issue is contingent on *security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
		Г
29	Date rights trading will end (if applicable)	

30	How do *security holders sell their entitlements in full through a broker?	
31	How do *security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do *security holders dispose of their entitlements (except by sale through a broker)?	
33	⁺ Despatch date	

Part 3 - Quotation of securities You need only complete this section if you are applying for quotation of securities 34 Type of securities (tick one) Shares (RNO) (a) (b) All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities Entities that have ticked box 34(a) Additional securities forming a new class of securities Tick to indicate you are providing the information or documents 35 If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders 36 If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over 37 A copy of any trust deed for the additional *securities **Entities that have ticked box 34(b)** 38 Number of securities for which *quotation is

39 Class of *securities for which quotation is sought

sought

Appendix 3B Page 7 01/08/2012

⁺ See chapter 19 for defined terms.

42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)		
		Number	†Class
	Example: In the case of restricted securities, end of restriction period		
41	Reason for request for quotation now (if issued upon conversion of another security, clearly identify that other security)		
	 the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
	If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?		

Quotation Agreement

- ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those ⁺securities should not be granted ⁺quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.
 - Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty
 - Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any ⁺securities to be quoted and that no-one has any right to return any ⁺securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the ⁺securities be quoted.
 - If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign Here:

Company Secretary
Phillip Hains

Print Name:

CFO

Date: Friday, 25th September 2015



Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for [†]eligible entities

Introduced 01/08/12

Part 1

*All calculations are based on a post consolidation basis.

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	493,724,305	
Add the following:		
Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	45,712,300	
Number of fully paid ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid ordinary securities that became fully paid in that 12 month period		
Note:		
Include only ordinary securities here – other classes of equity securities cannot be added		
Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed		
It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
"A"	539,438,635	

Step 2: Calculate 15% of "A"	
"B"	0.15

	[Note: this value cannot be changed]
Multiply "A" by 0.15	80,915,795

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:		
Under an exception in rule 7.2	75,000,000	
• Under rule 7.1A		
With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities 		
 Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed 		
• It may be useful to set out issues of securities on different dates as separate line items		
"C"	75,000,000	

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1	
"A" x 0.15 Note: number must be same as shown in Step 2	80,915,795
Subtract "C" Note: number must be same as shown in Step 3	75,000,000
<i>Total</i> ["A" x 0.15] – "C"	<u>5,915,795</u>
	[Note: this is the remaining placement capacity under rule 7.1]

Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A" Note: number must be same as shown in Step 1 of Part 1	539,438,635	

Step 2: Calculate 10% of "A"	
"D"	0.10 Note: This value cannot be changed
Multiply "A" by 0.10	53,943,864

Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used Insert number of equity securities issued or agreed Nil to be issued in that 12 month period under rule 7.1A Notes: • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items "E" Nil

⁺ See chapter 19 for defined terms. Appendix 3B Page 12

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10 Note: number must be same as shown in Step 2	53,943,864
Subtract "E" Note: number must be same as shown in Step 3	Nil
<i>Total</i> ["A" × 0.10] – "E"	53,943,864 Note: This is the remaining placement capacity under rule 7.1A

RHINOMED

ASX ANNOUNCEMENT

Notice Under Section 708A(5) of the Corporations Act [ASX Code: RNO]

25th September 2015

This notice is given under paragraph (5)(e) of section 708A of the Corporations Act.

Туре:	Shares (RNO)
Class/Description:	Ordinary Fully Paid Shares (RNO)
ASX Code:	RNO
Date of Issue	25 th September 2015
Number Issued:	10,937,500 Ordinary Shares (RNO)

Rhinomed Limited (the Company) intends to apply to Australian Stock Exchange Limited for quotation of the above securities.

Accordingly the Company gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the "Corporations Act") that:

- 1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the *Corporations Act*;
- 2. as at the date of this notice the Company has complied with:
 - (i) the provisions of Chapter 2M Corporations Act as they apply to the Company; and
 - (ii) section 674 Corporations Act; and
- 3. as at the date of this notice there is no "excluded information" (as defined in subsection 708A(7) of the Corporations Act) which is required to be disclosed by the Company.

For and on behalf of the Company,

Phillip Hains Company Secretary